

| | | | | | | | |
|--|--|--|------------------|---|---------------------------------|----------|----------------------------|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | Attorney Docket No. C-3169/1/US | Serial No. 09/451,641 | | |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | Applicant Gao, D. et al. | | | |
| | | | | Filing Date November 30, 1999 | Group No. 1615 | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial* | | Document Number | Publication Date | Name of Patentee or Applicant | Class | Subclass | Filing Date if Appropriate |
| | | 4,895,726 | Jan 23, 1990 | Curtet <i>et al.</i> | 424 | 456 | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| Examiner Initial* | | Document Number | Publication Date | Name of Patentee or Applicant | Class | Subclass | Translation Yes No |
| | | EP 0 001 247 | Apr 4, 1979 | Kanebo | A61K | 9/18 | |
| | | EP 0 256 933 | Feb 24, 1988 | Ethypharm | A61K | 31/235 | X |
| | | EP 0 330 532 | Aug 30, 1989 | Fournier Industrie et Santé | A61K | 9/16 | X |
| | | WO 96/38131 | Dec 5, 1996 | Glaxo | A61K | 9/14 | |
| | | WO 00/15195 | Mar 23, 2000 | Nycomed | A61K | 9/16 | |
| OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.) | | | | | | | |
| | | Amidon <i>et al.</i> (1995) A theoretical basis for a biopharmaceutical drug classification: the correlation of <i>in vitro</i> drug product dissolution and <i>in vivo</i> bioavailability. <i>Pharmaceutical Research</i> 12(3), 413-420. | | | | | |
| | | Ansel (1985) <i>Introduction to Pharmaceutical Dosage Forms</i> , 4th ed. Philadelphia: Lea & Febiger. Page cited: vii (first page of Contents). | | | | | |
| | | Aulton, ed. (1988) <i>Pharmaceutics: The Science of Dosage Form Design</i> . Edinburgh: Churchill Livingstone. Pages cited: 8, 156, 311, 330. | | | | | |
| | | Basit <i>et al.</i> (2001) The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly water-soluble drugs. <i>Pharmaceutical Research</i> 18(8), 1146-1150. | | | | | |
| | | Bauer <i>et al.</i> (1991) <i>Pharmazeutische Technologie</i> , 3rd ed. Stuttgart: Verlag. Pages cited: 104, 203. | | | | | |
| | | Berry & Nash, ed. (1993) <i>Pharmaceutical Process Validation</i> , 2nd ed. New York: Marcel Dekker. Pages cited: 174-181. | | | | | |
| | | British Pharmacopoeia 1993. Pages cited: Vol. I, 316; Vol. II, 753. | | | | | |
| | | Fincher <i>et al.</i> (1965) Effect of particle size on gastrointestinal absorption of sulfoxazole in dogs. <i>J. Pharm. Sci.</i> 54(5), 704-708. | | | | | |
| | | Ghosh <i>et al.</i> (1998) Product development studies on the tablet formulation of ibuprofen to improve bioavailability. <i>Drug Development & Industrial Pharmacy</i> 24(5), 473-477. | | | | | |
| | | Gibaldi (1991) <i>Biopharmaceutics and Clinical Pharmacokinetics</i> , 4th ed. Philadelphia: Lea & Febiger. Pages cited: 51, 52, 62. | | | | | |
| | | Hubbard <i>et al.</i> (1996) SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute non-surgical pain model. <i>J. Invest. Med.</i> 44(3), 293A. | | | | | |
| | | Hubbard <i>et al.</i> (1996) SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. <i>Arthritis & Rheumatism</i> 39 (Suppl. 9), S226, abstract 1188. | | | | | |
| Examiner | | | Date Considered | | | | |
| *Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | |
|--|--|--|-----------------|---|---------------------------------|
| Form PTO-1449 | | U.S. Department of Commerce Patent and Trademark Office | | Attorney Docket No. C-3169/1/US | Serial No. 09/451,641 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | Applicant Gao, D. et al. | |
| | | | | Filing Date November 30, 1999 | Group No. 1615 |
| | | | | | |
| OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.) | | | | | |
| | | Hubbard <i>et al.</i> (1997) Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis. <i>Arthritis & Rheumatism</i> 40, S51, abstract 125. | | | |
| | | Kaneniwa <i>et al.</i> (1973) Dissolution of slightly soluble drugs. I. Influence of particle size on dissolution behavior. <i>Chem. Pharm. Bull.</i> 22(8), 1699-1705. | | | |
| | | Kaneniwa <i>et al.</i> (1978) Dissolution of slightly soluble drugs. IV. Effect of particle size of sulfonamides on <i>in vitro</i> absorption rate, and their relation to solubility. <i>Chem. Pharm. Bull.</i> 26(3), 813-826. | | | |
| | | Lachman <i>et al.</i> , ed. (1986) <i>The Theory and Practice of Industrial Pharmacy</i> , 3rd ed. Philadelphia: Lea & Febiger. Pages cited: 21-45, 321-328. | | | |
| | | Levy (1963). Effect of particle size on dissolution and gastrointestinal absorption rates of pharmaceuticals. <i>Amer. J. Pharm.</i> , March 1963, 78-92. | | | |
| | | List (1985) <i>Arzneiformenlehre</i> , 4th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft. Pages cited: 210, 523. | | | |
| | | Martin (1993) <i>Physical Pharmacy</i> , 4th ed. Philadelphia: Lea & Febiger. Pages cited: 331, 423-436. | | | |
| | | Ridolfo <i>et al.</i> (1979) Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans. <i>J. Pharm. Sci.</i> 68(7), 850-852. | | | |
| | | Sprowls (1963) <i>Prescription Pharmacy</i> . Philadelphia: Lippincott. Page cited: 56. | | | |
| | | Voigt (1984) <i>Lehrbuch der Pharmazeutischen Technologie</i> , 5th ed. Basel: Verlag. Pages cited: 471, 472, 637. | | | |
| | | Wade & Weller (1994) <i>Handbook of Pharmaceutical Excipients</i> , 2nd ed. Washington: American Pharmaceutical Association. Pages cited: v, vi (Contents pages), 141, 163, 252, 280, 433, 448. | | | |
| | | Wadke <i>et al.</i> (1989) Preformulation testing. In Lieberman <i>et al.</i> , ed.: <i>Pharmaceutical Dosage Forms: Tablets</i> , Vol. 1. New York: Marcel Dekker. Pages cited: 5, 6. | | | |
| | | Zhao <i>et al.</i> (1997) Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. <i>Arthritis & Rheumatism</i> 40 (Suppl. 9), S88, abstract 348. | | | |
| Examiner | | | Date Considered | | |
| *Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |